DHR

Danaher Corporation

HealthcareDiagnostics & ResearchNASDAQ

$182.67

+$9.84 (5.39%)today

Conviction

0/ 10

Fair Value$263.86

Upside+44.45%

Signal0

Market Cap$134.4B

52W Range$171–$242.80

Next EarningsApr 21

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$81.10

Current Price$181.52

Upside / Down-55.3%

P(Undervalued)0.0%

P(20%+ Up)0.0%

P(15%+ Down)100.0%

Fair Value Distribution — percentile bands

0.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

17.8%/yr

±5.1% · revenue growth to justify current price

FCF-Based Reverse DCF

15.3%/yr

±3.1% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Quick Take

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

Trailing P/E37.8x

Forward P/E20.9x

P/S5.5x

EPS (TTM)$5.03

Analyst Target$263.86

Analyst Upside44.4%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kFeb 28

Conviction: unchanged

DHR 10-K FY2025: Bioprocessing Recovery On Track, Life Sciences Drag, Masimo Gamble

Danaher delivered modest FY2025 recovery: .6B revenue (+3.0%), adj. EPS .80 (+4.5%), FCF .3B. Bioprocessing strengthening but Life Sciences segment profit collapsed 57%. Pending Masimo acquisition add...